CLL | Tumor

Cirmtuzumab Plus Imbruvica Led to Increased Response Rates in MCL and CLL

June 7th 2021, 9:00pm

Cirmtuzumab plus Imbruvica led to an 83.3% overall response rate, with 38.9% complete response and 44.4% partial response rate, in patients with mantle cell lymphoma and chronic lymphocytic leukemia.

Imbruvica Plus Ublituximab Safely Improves Response Rate for High-Risk Chronic Lymphocytic Leukemia

April 23rd 2021, 9:00pm

Imbruvica combined with ublituximab improved overall response rate and progression-free survival for relapsed/refractory high-risk chronic lymphocytic leukemia with minimal residual disease negativity.

Gazyva With Chemotherapy Shows Promise for Chronic Lymphocytic Leukemia

April 22nd 2021, 9:00pm

Final analysis of a phase 3 study demonstrates a tolerable toxicity profile for Gazvya in combination with chemotherapy for patients with ether first-line or relapsed/refractory chronic lymphocytic leukemia.

Imbruvica Plus Novel Agent May Improve Progression-Free Survival in Chronic Lymphocytic Leukemia

March 3rd 2021, 7:00pm

Patients treated with Imbruvica plus TG-1101 had an overall response rate of 83% compared with 65% in those treated with Imbruvica alone.

First Patient to Receive CAR-T Cell Therapy Dies, Cancer Organizations Appeal to President Biden for COVID-19 Vaccine Priority Access, and More

February 19th 2021, 4:00pm

From the death of Bill Ludwig, the first patient to receive CAR-T cell therapy to treat his end-stage CLL, to a letter to the President urging him to grant patients with cancer and survivors priority access to the COVID-19 vaccine, here’s what’s happening in the cancer space this week.

Adding to the Regimen: NCCN Updates in Leukemia and Lymphoma

February 15th 2021, 4:00pm

The NCCN has updated its recommendations for chronic lymphocytic leukemia and small lymphocytic lymphoma to now include Brukinsa as a first- and second-line therapy in a subgroup of patients.

Addressing Unmet Needs in CLL

February 2nd 2021, 9:30pm

CLL: An Early Clinical Trial With Ibrutinib

February 2nd 2021, 5:15am

CAR T-Cells: Refining CLL Therapy With Clinical Trials

February 2nd 2021, 5:00am

CLL Versus Other Leukemia Types

February 2nd 2021, 5:00am